Journal article
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy
Abstract
OBJECTIVES: The association of a change in serum alkaline phosphatase (ALP) with overall survival OS in men with metastatic castration-resistant prostate cancer (CRPC) receiving chemotherapy is unknown. We evaluated the association of changes in ALP within 90 days with OS in men with CRPC and bone metastases treated with docetaxel or mitoxantrone in the TAX327 trial.
MATERIALS AND METHODS: Eligible patients included those with bony metastatic …
Authors
Sonpavde; Pond GR; Berry WR; de Wit R; Armstrong AJ; Eisenberger MA; Tannock IF
Journal
Urologic Oncology Seminars and Original Investigations, Vol. 30, No. 5, pp. 607–613
Publisher
Elsevier
Publication Date
9 2012
DOI
10.1016/j.urolonc.2010.07.002
ISSN
1078-1439
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAlkaline PhosphataseAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsDocetaxelHumansKaplan-Meier EstimateMaleMiddle AgedMitoxantroneOrchiectomyOutcome Assessment, Health CarePrognosisProportional Hazards ModelsProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesTaxoidsTime Factors